Advancing Understanding of Non-Small Cell Lung Cancer with Multiplexed Antibody-Based Spatial Imaging Technologies.
Simon GrayChristian Hermann OttensmeierPublished in: Cancers (2023)
Non-small cell lung cancer (NSCLC) remains a cause of significant morbidity and mortality, despite significant advances made in its treatment using immune checkpoint inhibitors (ICIs) over the last decade; while a minority experience prolonged responses with ICIs, benefit is limited for most patients. The development of multiplexed antibody-based (MAB) spatial tissue imaging technologies has revolutionised analysis of the tumour microenvironment (TME), enabling identification of a wide range of cell types and subtypes, and analysis of the spatial relationships and interactions between them. Such study has the potential to translate into a greater understanding of treatment susceptibility and resistance, factors influencing prognosis and recurrence risk, and identification of novel therapeutic approaches and rational treatment combinations to improve patient outcomes in the clinic. Herein we review studies that have leveraged MAB technologies to deliver novel insights into the TME of NSCLC.
Keyphrases
- small cell lung cancer
- high resolution
- single cell
- end stage renal disease
- chronic kidney disease
- primary care
- newly diagnosed
- mesenchymal stem cells
- prognostic factors
- advanced non small cell lung cancer
- risk assessment
- patient reported outcomes
- peritoneal dialysis
- fluorescence imaging
- monoclonal antibody
- patient reported